Rock Springs Capital Management LP Purchases 59,243 Shares of Dyne Therapeutics, Inc. $DYN

Rock Springs Capital Management LP boosted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 6.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 972,198 shares of the company’s stock after buying an additional 59,243 shares during the period. Rock Springs Capital Management LP’s holdings in Dyne Therapeutics were worth $17,626,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Quantinno Capital Management LP grew its holdings in Dyne Therapeutics by 53.2% during the 1st quarter. Quantinno Capital Management LP now owns 19,297 shares of the company’s stock worth $350,000 after acquiring an additional 6,704 shares during the period. Orbimed Advisors LLC lifted its stake in shares of Dyne Therapeutics by 32.5% in the 1st quarter. Orbimed Advisors LLC now owns 2,917,884 shares of the company’s stock valued at $52,901,000 after purchasing an additional 715,700 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Dyne Therapeutics by 13.4% in the 1st quarter. Renaissance Technologies LLC now owns 533,600 shares of the company’s stock valued at $9,674,000 after purchasing an additional 62,955 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Dyne Therapeutics by 870.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 951,589 shares of the company’s stock valued at $17,244,000 after purchasing an additional 853,515 shares during the period. Finally, Swiss National Bank boosted its position in shares of Dyne Therapeutics by 2.5% during the 1st quarter. Swiss National Bank now owns 228,100 shares of the company’s stock valued at $4,135,000 after purchasing an additional 5,600 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $25.63 on Tuesday. The firm has a market capitalization of $4.78 billion, a P/E ratio of -7.96 and a beta of 1.06. The firm’s 50-day moving average price is $20.56 and its 200-day moving average price is $18.67. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 1-year low of $8.88 and a 1-year high of $26.12.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the company earned ($1.05) earnings per share. Equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other news, CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares in the company, valued at $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jason P. Rhodes sold 297,211 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $23.26, for a total value of $6,913,127.86. Following the sale, the director owned 2,962 shares of the company’s stock, valued at approximately $68,896.12. This represents a 99.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders bought 9,000 shares of company stock valued at $156,800 and sold 1,665,542 shares valued at $36,321,576. Insiders own 9.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. TD Cowen began coverage on Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating for the company. Evercore set a $33.00 price target on Dyne Therapeutics in a research note on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Sanford C. Bernstein raised their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.